
Hereditary cancers: diagnosed patients are only the tip of the iceberg
Although knowledge on pathogenic germline variants has improved over the years, researchers are hunting for new genetic causes of cancer to better identify families at higher risk to develop the disease

Despite success of targeted therapies, personalised medicine is not yet a reality in ovarian cancer
Expert says widely applicable predictive testing is needed to improve prevention, diagnosis and treatment

Innovation is creating new ways to support oncologists
How ESMO is transforming the challenges from the COVID-19 pandemic into opportunities to re-shape the future of the oncology community

Patients need more support to navigate precision oncology
As the complexity of the cancer landscape increases, miscommunication and misunderstanding emerge as major obstacles to patient self-determination

Predict the next evolutionary move of cancer: a feasible winning strategy?
Tumour evolution is one of the primary reasons for resistance to treatment and researchers are now learning how to use it to lead tumours down a dead end

Momentous achievements in oncology treatment: where will the wave of innovation take cancer care?
Efficacy of targeted therapies has enabled unprecedented survival gains in the last few years, but Prof. Jean-Charles Soria believes overcoming drug resistance is likely to be a local battle fought in the tumour microenvironment

CAR-T cell therapy in solid tumours: will we ever replicate the success rates achieved in blood cancers?
Despite early promises, advances are needed in targeting tumour-specific epitopes, overcoming the tumour microenvironment, and automating CAR-T production, explains Prof. Ulrike Köhl

Artificial intelligence: a game-changer for the future of cancer care
Faced with an explosion in the complexity of genomic, imaging and clinical data, AI is rapidly becoming an indispensable tool for oncologists.

Breast cancer treatment should be tailored to the tumour biology – not to its hormone-receptor status alone
New insights into breast cancer immunology and genomics support further segmentation of patient subgroups and treatment approaches, says Prof. Sherene Loi

Lung cancer screening – an accessible option to all at-risk smokers?
While mature data from trials have demonstrated that periodic rounds of low-dose CT scan reduce lung-cancer related mortality, major issues are now implementation of screening on a large-scale and how to engage the target population